Virpax Pharmaceuticals, Inc. (VRPX)
| Market Cap | 49.60M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.66M |
| Shares Out | 4.51M |
| EPS (ttm) | -0.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
News
West Chester, Pennsylvania-based Virpax was founded to create new formulations for the use of existing, approved drugs for various forms of pain management applications.
Virpax Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ stock exchange.
About VRPX
Virpax Pharmaceuticals is a preclinical stage biopharmaceutical company focused on becoming a global leader in pain management by developing and delivering innovative non-opioid and non-addictive pharmaceutical products using new drug delivery systems and technology. We are developing branded pharmaceutical product candidates for pain management by using advanced technology in an effort to enhance patients’ quality of life. We have exclusive global rights to develop, sell and export (among other rights) a proprietary patented nonsteroid anti-... [Read more...]
| Industry Pharmaceutical Preparations | IPO Date Pending |
| CEO Anthony Mack | Employees 2 |
| Stock Exchange NASDAQ | Ticker Symbol VRPX |